Abstract
Atomic structures of Tau involved in Alzheimer’s disease complexed with small molecule binders are the first step to define the Tau pharmacophore, leading the way to a structure-based design of improved diagnostics and therapeutics. Yet the partially disordered and polymorphic nature of Tau hinders structural analyses. Fortunately, short segments from amyloid proteins, which exhibit similar biophysical properties to the full-length proteins, also form fibrils and oligomers, and their atomic structures can be determined using X-ray microcrystallography. Such structures were successfully used to design amyloid inhibitors. This chapter describes experimental procedures used to determine crystal structures of Tau peptide segments in complex with small-molecule binders.
| Original language | English |
|---|---|
| Title of host publication | Methods in Molecular Biology |
| Publisher | Humana Press Inc. |
| Pages | 89-100 |
| Number of pages | 12 |
| DOIs | |
| State | Published - 2017 |
| Externally published | Yes |
Publication series
| Name | Methods in Molecular Biology |
|---|---|
| Volume | 1523 |
| ISSN (Print) | 1064-3745 |
Bibliographical note
Publisher Copyright:© Springer Science+Business Media New York 2017.
Keywords
- Alzheimer’s disease
- Amyloid-like peptides
- Microcrystallography
- Microcrystals
- Pharmacophore
- Small molecules
- Tau
Fingerprint
Dive into the research topics of 'X-ray structural study of amyloid-like fibrils of tau peptides bound to small-molecule ligands'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver